Page last updated: 2024-11-04

vorinostat and Papillomavirus Infections

vorinostat has been researched along with Papillomavirus Infections in 3 studies

Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).

Papillomavirus Infections: Neoplasms of the skin and mucous membranes caused by papillomaviruses. They are usually benign but some have a high risk for malignant progression.

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Banerjee, NS1
Moore, DW1
Broker, TR1
Chow, LT1
Citro, S1
Bellini, A1
Miccolo, C1
Ghiani, L1
Carey, TE1
Chiocca, S1
Yuan, H1
Myers, S1
Wang, J1
Zhou, D1
Woo, JA1
Kallakury, B1
Ju, A1
Bazylewicz, M1
Carter, YM1
Albanese, C1
Grant, N1
Shad, A1
Dritschilo, A1
Liu, X1
Schlegel, R1

Other Studies

3 other studies available for vorinostat and Papillomavirus Infections

ArticleYear
Vorinostat, a pan-HDAC inhibitor, abrogates productive HPV-18 DNA amplification.
    Proceedings of the National Academy of Sciences of the United States of America, 2018, 11-20, Volume: 115, Issue:47

    Topics: Apoptosis; Bcl-2-Like Protein 11; Cells, Cultured; DNA Repair; DNA Replication; DNA-Binding Proteins

2018
Synergistic antitumour activity of HDAC inhibitor SAHA and EGFR inhibitor gefitinib in head and neck cancer: a key role for ΔNp63α.
    British journal of cancer, 2019, Volume: 120, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Synergism; Gefitinib; Histone Deacetylase Inhib

2019
Use of reprogrammed cells to identify therapy for respiratory papillomatosis.
    The New England journal of medicine, 2012, Sep-27, Volume: 367, Issue:13

    Topics: Antineoplastic Agents; Cells, Cultured; DNA, Viral; Gene Expression; Genome, Viral; Human papillomav

2012